Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corporation (NASDAQ: RLYB) is a clinical-stage biotechnology company whose news flow centers on the development of therapies for severe and rare diseases. Company press releases and SEC filings highlight progress across its pipeline, with particular emphasis on RLYB116, a differentiated C5 inhibitor being evaluated in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study designed to demonstrate complete and sustained complement inhibition with favorable tolerability.
Investors following RLYB news can expect regular updates on clinical milestones for RLYB116, including cohort dosing, interim data, and the program’s initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS), two hematologic conditions with significant unmet need. Rallybio also issues news on its preclinical programs, such as RLYB332, a long-acting monoclonal anti-matriptase-2 antibody for diseases of iron overload, and on the ENPP1 inhibitor program REV102 for hypophosphatasia (HPP), which originated from a joint venture with Recursion Pharmaceuticals.
RLYB news releases frequently cover financial results, cash runway guidance, and portfolio decisions, including the discontinuation of the RLYB212 program for fetal and neonatal alloimmune thrombocytopenia (FNAIT) based on Phase 2 pharmacokinetic data. Corporate and transaction updates, such as the sale of Rallybio’s interest in REV102 to Recursion for equity, milestones, and potential royalties, as well as workforce and cost-structure changes, are also disclosed.
This news page aggregates these company-issued updates, earnings announcements, and material event disclosures, offering a centralized view of Rallybio’s clinical progress, strategic transactions, and capital position for those tracking RLYB stock and its rare disease pipeline.
Rallybio Corporation (Nasdaq: RLYB) has priced an underwritten public offering of 5,000,001 shares at $6.00 each and pre-funded warrants for up to 3,333,388 shares at $5.9999 each. The total gross proceeds are anticipated to be around
Rallybio Corporation (Nasdaq: RLYB) announced a proposed public offering of $75 million in common stock and pre-funded warrants. The offering aims to grant underwriters a 30-day option to purchase an additional 15% of the securities sold. The transaction, which is subject to market conditions, is managed by J.P. Morgan, Cowen, and Evercore ISI. The offering is conducted under an effective shelf registration statement with the SEC, which may affect shareholders. Investors are advised to review the preliminary prospectus for comprehensive details.
Rallybio Corporation (Nasdaq: RLYB) reported financial results for Q3 2022, showing a net loss of $18.4 million and R&D expenses of $12.1 million. The company presented promising preliminary results from the Phase 1b study of RLYB212, demonstrating rapid platelet elimination. Positive topline results from the Phase 1 study of RLYB116 indicated over a 99% reduction in free C5 levels, with potential for less frequent dosing. Rallybio's cash position as of September 30, 2022, was $132.4 million, sufficient to fund operations into Q1 2024.
Rallybio Corporation (Nasdaq: RLYB) has reported positive topline results from its Phase 1 study of RLYB116, a subcutaneous C5 inhibitor. The study demonstrated a reduction of >99% in free C5 within 24 hours after a 100 mg dose in healthy participants, with a terminal elimination half-life exceeding 300 hours. The drug was well-tolerated with mild or moderate adverse events noted. A Phase 1 multiple ascending dose study is set to begin in the first quarter of 2023, potentially leading to improved quality of life for patients with complement-mediated diseases.
Rallybio Corporation announced promising preliminary results from its ongoing Phase 1b study of RLYB212, an anti-HPA-1a monoclonal antibody aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The data indicates that RLYB212 rapidly eliminates transfused HPA-1a positive platelets, achieving over 90% reduction in mean platelet elimination half-life compared to placebo. Safety assessments show acceptable tolerability with no serious adverse events. Rallybio plans to disclose comprehensive proof-of-concept data in the first quarter of 2023.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology firm, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 3:10 p.m. ET in Everett, MA. A live webcast can be viewed on Rallybio's website, with an archived replay available for 30 days. Founded in January 2018, Rallybio focuses on developing therapies for severe and rare diseases, particularly in hematology and immuno-inflammation. The company is based in New Haven, Connecticut, and collaborates with the University of Connecticut.
Rallybio Corporation (Nasdaq: RLYB) reported second-quarter financial results for 2022, highlighting progress in its clinical pipeline. The Phase 1b study of RLYB212 shows promising data in eliminating transfused HPA-1a positive platelets. R&D expenses increased to $10.1 million, primarily due to asset acquisition for RLYB331, while G&A expenses rose to $7.5 million. The net loss for the quarter stood at $17.6 million, with net loss per share at $0.57. As of June 30, 2022, the company had cash reserves of $147.4 million, sufficient to fund operations into Q1 2024.
Rallybio Corporation (NASDAQ: RLYB) announced the appointment of Wendy K. Chung, M.D., Ph.D., to its Board of Directors. Dr. Chung brings over 20 years of experience in human genetic research and is well-acquainted with the challenges in developing therapies for rare diseases. Her expertise is expected to enhance Rallybio's product portfolio and pipeline development. Chairman and CEO Martin Mackay emphasized the valuable insights Dr. Chung will provide as the company focuses on life-transforming therapies for severe and rare diseases.
Rallybio Corporation (Nasdaq: RLYB) announces the retirement of Chief Financial Officer Jeffrey Fryer, who will remain until the appointment of a successor. The company has initiated an external search for a new CFO. Fryer expressed satisfaction with his time at Rallybio, citing a strong financial position and growing pipeline. Rallybio is a clinical-stage biotechnology firm focused on developing therapies for severe and rare diseases.
Rallybio Corporation (Nasdaq: RLYB) announced its participation in two major investor conferences. The first is the Jefferies Healthcare Conference in New York on June 8, 2022, at 10:30 a.m. ET. The second is the JMP Securities Life Sciences Conference, also in New York, scheduled for June 15, 2022, at 10:30 a.m. ET. Investors can access a live webcast of both presentations through Rallybio’s website, with replays available for 30 days post-event. Rallybio focuses on therapies for severe and rare diseases, established in January 2018.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
